Eiger BioPharmaceuticals, Inc.: M&A transaction — Eiger sells Avexitide to Amylyx for $35.1M in bankruptcy sale closed July 9

Eiger BioPharmaceuticals, Inc.

Sold Avexitide asset to Amylyx Pharmaceuticals for $35.1M plus assumed cure costs and liabilities.
Bankruptcy Court approved sale on June 26, 2024; transaction closed July 9, 2024.
Amylyx will handle development, manufacturing, and commercialization of Avexitide.
Eiger's common stock (EIGRQ) trades on OTC Pink; company cautions of potential total loss for securityholders.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Eiger BioPharmaceuticals, Inc. completed a disposition involving Amylyx Pharmaceuticals, Inc. for $35.1 million (closed 2024-07-09).

Action: disposition
Counterparty: Amylyx Pharmaceuticals, Inc.
Consideration: $35.1 million
Closing: 2024-07-09

Exact text from the filing

the Company’s rights, title and interests in, to and under those assets and interests used by the Company in the development, manufacture and commercialization of Avexitide for $35.1 million, plus the aggregate amount of determined cure costs and assumed liabilities. At a hearing held on June 26, 2024, the Bankruptcy Court approved the sale of the Company’s Avexitide

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001193125-24-177016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.